Howard Chang wasn’t looking for a change from his job at Stanford, where he worked as both a genomic researcher and a dermatologist. His busy lab there was focused on understanding how regulatory programmes drive disease — unveiling for example how long-non-coding RNA (lncRNA) underpins autoimmunity in women and how extrachromosomal DNA (ecDNA) fuels cancer. And with five biotech startups already under his belt, Chang saw a path to transform these big ideas into drugs. But when he got a call from Amgen’s head of R&D Jay Bradner about joining the big biotech team, he couldn’t resist the change.
Enjoying our latest content?
Login or create an account to continue
Access the most recent journalism from Nature’s award-winning team
Explore the latest features & opinion covering groundbreaking research
or
Interviewed by Asher Mullard
The interview was edited for length and clarity.